A phase 3 study assessing the use pregabalin as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint to ...
BOSTON — Preliminary results from a meta-analysis have shown that antiepileptic drugs (AEDs) approved for adults with primary generalized tonic-clonic (PGTC) seizures are also effective in children ...
GlaxoSmithKline’s antiseizure drug, Lamictal® (lamotrigine), was approved for a new epilepsy indication—one of the most serious forms of epilepsy, primary generalized tonic-clonic (PGTC) seizures.
ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of FINTEPLA ...
Phase III study demonstrates significant improvements in seizure freedom and seizure reduction in people living with this severe type of epilepsy Fycompa ® (perampanel) today received positive opinion ...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) ...
The Key Tonic clonic Seizure Companiesin theamrket include - Emory University, Pfizer, GlaxoSmithKline, Eisai Inc., Xenon Pharmaceuticals, UCB Pharma, Johnson ...
The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback